Levels of serum IgG and IgG4 antibodies specific to mite (Dermatophagoides farinae) were estimated by an indirect enzyme-linked immunosorbent assay in patients with nasal allergy. A high IgG antibody titer (antibody titer higher than 20) was observed in 39.5% (90/228) of patients with nasal allergy to mite, and IgG4 antibody was detectable in 31.6% (78/228). There were no differences from the point of view of sex or age in the quantity of IgG and IgG4 antibodies. In patients with a low IgE antibody titer to mite (RAST score lower than 1), a high IgG antibody titer was observed among 34.7% (17/49), and IgG4 antibody was detectable in 30.6% (15/49). In the patients with bronchial asthma complications, a high incidence in the number of individuals with detectable IgG4 antibody was observed (p<0.005). In the patients who had received long term immunotherapy by mite (n:122, for an average of 20 months), a high IgG antibody titer was observed in 67.2% (82/122), and IgG4 antibody was detectable in 62.3% (76/122). Therefore, we assumed IgG and IgG4 antibodies were increased by immunotherapy. Furthermore a correlation coefficient in the ratio of IgG4 antibody titer to IgG antibody titer was higher in patients who had received immunotherapy (n: 122, r=0.4720, p<0.005) than in patients who had not received immunotherapy (n=228, r=3165, p<0.005). From these data, we assumed that an increase in IgG antibodies might be caused mainly by an increase in the IgG4 antibody. In order to test whether these antibodies act as blocking antibodies, we selected another 46 patients who had started mite immunotherapy at the same time. IgG and IgG4 antibodies in their serum were measured at 3 points: the beginning of therapy, 12 weeks later, and 24 weeks later. IgG and IgG4 antibodies in their serum began to rise at 12 weeks, and kept increasing to the 24th week (IgG:p<0.02, IgG4:p<0.01). Although both antibodies were increased by immunotherapy, the increase had no influence on the clinical improvement of the allergic symptoms. From this study, it was shown that serum IgG and IgG4 antibodies specific to mite did not act as "blocking antibodies" in patients with nasal allergy to mite.
View full abstract